ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

He, Yanxia; Gao, Yan; Ping, Liqin; He, Haixia; Huang, Cheng; Bai, Bing; Wang, Xiaoxiao; Li, Zhiming; Cai, Qingqing; Huang, Yuhua; Pan, Xueyi; Zeng, Wenbin; Liu, Yanan; Huang, Huiqiang*广东药学院; 中山大学; 1
Journal of Cancer Research and Clinical Oncology2023-5DOI: 10.1007/s00432-022-04147-2
4被引5阅读
引用收藏
分享

摘要

Purpose Anti-PD-1 antibody (anti-PD-1 mAb) showed favorable outcomes in some patients with relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL). However, the role of anti-PD-1 antibody in NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (NK/T-LAHS) remains unclear. Here, we evaluated the efficacy and toxicity of anti-PD-1 antibody-based treatment in NK/T-LAHS patients. Methods The clinical data of 98 patients diagnosed with NK/T-LAHS at Sun Yat-sen University Cancer Center and the First Affiliated Hospital of Guangdong Pharmaceutical University from May 2014 to November 2021 were retrospectively analyzed. All patients received anti-HLH [HLH-2004 (etoposide, dexamethasone, cyclosporine A) or DEP-based (liposomal doxorubicin, etoposide, methylprednisolone)] regimen and sequential anti-ENKTL chemotherapy (ChT) combined with anti-PD-1 antibody or not. Results The overall response rate (ORR) of the anti-PD-1 mAb plus ChT regimens was higher than that of the ChT regimens (73.3% vs. 45.5%, P = 0.041). The toxicity of the anti-PD-1 mAb plus ChT regimens was tolerable. Except for higher rate of neutropenia, no significant difference in adverse events (AEs) was observed between the two groups. When the optimal response to anti-ENKTL was achieved, the median EBV DNA levels in patients who received anti-PD-1 mAb plus ChT were significantly lower than patients who received ChT only (878 copies/mL vs. 18,600 copies/mL, P = 0.001). With a median follow-up of 26.6 months (range 0-65.9 months), the median overall survival (mOS) was 3.5 months (95% CI:2.3-4.7 months). Patients treated with anti-PD-1 mAb plus ChT experienced a longer mOS than those who received ChT only [5.2 months (95% CI: 2.5-7.8 months) vs. 1.5 months (95% CI: 0.5-2.6 months), P = 0.002]. Cox multivariate analysis found that anti-PD-1 mAb was an independent prognostic factor for all NK/T-LAHS patients. Conclusion In conclusion, anti-PD-1 mAb combined with ChT regimens seemed to be associated with prolonged survival in NK/T-LAHS patients and may represent a potentially promising treatment strategy for this population.

学科与关键词

关键词
Hemophagocytic lymphohistiocytosisExtranodal NKT-cell lymphomaAnti-PD-1 antibodyEpstein-Barr virus
相关
加载中…
  • First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study
    Wang, Xiaoxiao; Wen, Lei; Liao, Jing; Feng, Yanfen; Li, Yuhong; Zhou, Zhaoming; Zhou, Cheng*; Huang, Huiqiang*British Journal of Haematology, 2023, 202(4): 812-824.
  • PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study
    Yan, Gao; Zhang, Liling; Li, Wenyu; Wei, Xu; Feng, Ru; Li, Xue-Ping; Chen, Yu; Wu, Huijing; Wang, Xiaoxiao; Bai, Bing; Huang, Huiqiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
  • Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
    Que, Yi; Wang, Juan; Zhu, Jia; Li, Na; Huang, Junting; Lu, Suying; Sun, Feifei; Zhang, Lian; Zhen, Zijun; Zhang, Li; Cai, Ruiqing; Guo, Haixia*; Sun, Xiaofei*; Zhang, Yizhuo*Frontiers in Immunology, 2021, 12: 647733.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Cancer Research and Clinical Oncology
发表日期
2023-05
卷期
第 149 卷, 第 5 期
页码
2017-2027
DOI
10.1007/s00432-022-04147-2
语言
ENGLISH
成果收录
SCIE
资助标注
National Science & Technology Major Project [2017ZX09304021]; National Natural Science Foundation of China [82170188, 81970176]

作者

  • H

    He, Yanxia (第一作者)

    sun yat sen univ

  • G

    Gao, Yan

    sun yat sen univ

查看全部 14 位作者收起作者
  • P

    Ping, Liqin

    sun yat sen univ

  • H

    He, Haixia

    sun yat sen univ

  • H

    Huang, Cheng

    sun yat sen univ

  • B

    Bai, Bing

    sun yat sen univ

  • W

    Wang, Xiaoxiao

    sun yat sen univ

  • L

    Li, Zhiming

    sun yat sen univ

  • C

    Cai, Qingqing

    sun yat sen univ

  • H

    Huang, Yuhua

    sun yat sen univ

  • P

    Pan, Xueyi

    1 · guangdong pharmaceut univ

  • Z

    Zeng, Wenbin

    1 · guangdong pharmaceut univ

  • L

    Liu, Yanan

    1 · guangdong pharmaceut univ

  • H

    Huang, Huiqiang (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417